851224-83-4

Usage

Explanation

The compound's full name, which describes its structure and components.

Explanation

The main structural components of the compound, which contribute to its unique properties and reactivity.

Explanation

The specific functional groups present in the compound, which play a role in its chemical behavior and potential applications.

Explanation

The compound's ability to be easily modified or functionalized for specific applications in the chemical and pharmaceutical industries.

Explanation

The primary areas in which the compound is utilized, highlighting its importance in the development of new chemical and pharmaceutical products.

Explanation

The compound's solubility properties, which can influence its use in various chemical reactions and processes.

Explanation

The compound's stability, which is important for its storage, handling, and use in various applications.

Explanation

The need for caution when working with the compound, as it may have hazardous properties or pose risks to human health and the environment.

Explanation

The compound's purity, which is crucial for its effectiveness and reliability in various applications.

Explanation

Alternative names for the compound, which may be used in different contexts or by different researchers and organizations.

Structure

Thiadiazole ring, phenyl group, trifluoromethyl group, and methanesulfonate (ester) group

Functional Groups

Thiadiazole, phenyl, trifluoromethyl, and methanesulfonate ester

Reactivity

Versatile compound with potential for modification and functionalization

Applications

Organic synthesis, pharmaceutical research, and as a building block for the synthesis of various organic compounds

Solubility

Soluble in organic solvents

Stability

Stable under normal conditions

Safety

Handle with care due to potential reactivity and toxicity

Purity

Typically synthesized with high purity for use in research and development

Synonyms

1,2,4-Thiadiazol-5-ylmethanol, 3-[4-(trifluoromethyl)phenyl]-, methanesulfonate (ester)

Upstream product

• 851224-81-2 [3-(4-trifluoromethylphenyl)[1,2,4]thiadiazol-5-yl]methanol 
• 124-63-0 methanesulfonyl chloride 
• 329-15-7 4-trifluoromethyl-phenyl acetyl chloride 
• 1891-90-3 p-trifluoromethylbenzamide 
• 851224-79-8 5-(4-trifluoromethylphenyl)[1,3,4]oxathiazol-2-one 
• 851224-80-1 3-(4-trifluoromethylphenyl)[1,2,4]thiadiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 851224-82-3 {2-methyl-4-[3-(4-trifluoromethylphenyl)[1,2,4]thiadiazol-5-ylmethylsulfanyl]phenoxy}acetic acid ethyl ester 
• 851224-87-8 2-methyl-4-[3-(4-trifluoromethylphenyl)[1,2,4]thiadiazol-5-ylmethylsulfanyl]phenol 
• 851224-64-1 2-methyl-2-{2-methyl-4-[3-(4-trifluoromethylphenyl)[1,2,4]thiadiazol-5-ylmethoxy]phenoxy}propionic acid ethyl ester 
• 851224-84-5 4-[3-(4-trifluoromethyl-phenyl)-[1,2,4]thiadiazol-5-ylmethylsulfanyl]-phenol 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors α/δ dual agonists

Replacement of the methyl-thiazole moiety of GW501516 (a PPARδ selective agonist) with [1,2,4]thiadiazole gave compound 21 which unexpectedly displayed submicromolar potency as a partial agonist at PPARα in addition to the high potency at PPARδ. A structu

Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors α and δ

Cardiovascular disease is the most common cause of morbidity and mortality in developed nations. To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated recept

Synthesis of a 5-((Aryloxy)methyl)-3-(4-(trifluoromethyl)phenyl)[1,2,4] thiadiazole derivative: A promising PPARα,δ agonist

The preparation of the PPARα,δ agonist 2-methyl-2-(2-methyl-4- (3-(4-(trifluoromethyl)phenyl)[1,2,4]thiadiazol-5-ylmethoxy)phenoxy)propionic acid sodium salt (17) is described and compared with earlier in-house preparations of this important target compound. Key concerns around a large-scale synthesis of this thiadiazole derivative were a large number of purification steps, the use of dichlorobenzene as a solvent, and a possible large-scale Baeyer-Villiger oxidation. This paper describes a straightforward preparation of the target agonist using methylhydroquinone (MHQ) as an inexpensive precursor that eliminates the need of an oxidation step.

4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.